1. Home
  2. TLSI vs BHST Comparison

TLSI vs BHST Comparison

Compare TLSI & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLSI
  • BHST
  • Stock Information
  • Founded
  • TLSI 2010
  • BHST 2007
  • Country
  • TLSI United States
  • BHST Canada
  • Employees
  • TLSI N/A
  • BHST N/A
  • Industry
  • TLSI Medical Specialities
  • BHST
  • Sector
  • TLSI Health Care
  • BHST
  • Exchange
  • TLSI Nasdaq
  • BHST Nasdaq
  • Market Cap
  • TLSI 150.0M
  • BHST 166.4M
  • IPO Year
  • TLSI N/A
  • BHST N/A
  • Fundamental
  • Price
  • TLSI $5.05
  • BHST $7.47
  • Analyst Decision
  • TLSI Strong Buy
  • BHST Strong Buy
  • Analyst Count
  • TLSI 5
  • BHST 2
  • Target Price
  • TLSI $10.90
  • BHST $13.00
  • AVG Volume (30 Days)
  • TLSI 112.5K
  • BHST 21.0K
  • Earning Date
  • TLSI 08-12-2025
  • BHST 08-11-2025
  • Dividend Yield
  • TLSI N/A
  • BHST N/A
  • EPS Growth
  • TLSI N/A
  • BHST N/A
  • EPS
  • TLSI N/A
  • BHST N/A
  • Revenue
  • TLSI $35,990,000.00
  • BHST $30,192,000.00
  • Revenue This Year
  • TLSI $56.79
  • BHST $116.40
  • Revenue Next Year
  • TLSI $54.15
  • BHST $55.91
  • P/E Ratio
  • TLSI N/A
  • BHST N/A
  • Revenue Growth
  • TLSI 45.50
  • BHST 57.83
  • 52 Week Low
  • TLSI $3.42
  • BHST $4.66
  • 52 Week High
  • TLSI $5.88
  • BHST $9.90
  • Technical
  • Relative Strength Index (RSI)
  • TLSI 55.11
  • BHST 39.71
  • Support Level
  • TLSI $4.80
  • BHST $7.10
  • Resistance Level
  • TLSI $5.24
  • BHST $9.45
  • Average True Range (ATR)
  • TLSI 0.35
  • BHST 0.50
  • MACD
  • TLSI 0.02
  • BHST -0.21
  • Stochastic Oscillator
  • TLSI 72.18
  • BHST 15.10

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

About BHST BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

Share on Social Networks: